Oral Anti-Diabetic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By End Users, By Region and Competition, 2020-2030F

Description

The Global Oral Anti-Diabetic Drugs Market was valued at USD 18.02 Billion in 2024 and is projected to reach USD 25.94 Billion by 2030, growing at a CAGR of 6.22% during the forecast period. This market has witnessed notable growth due to the rising global prevalence of diabetes and continuous advancements in pharmaceutical research. Diabetes, driven by factors such as aging populations, sedentary lifestyles, and unhealthy diets, has created a vast and growing patient pool. As a result, the need for diverse and effective oral treatment options has surged. The market encompasses a wide array of drug classes, including Sulfonylureas, Biguanides, DPP-4 Inhibitors, SGLT2 Inhibitors, and GLP-1 Receptor Agonists, each addressing different mechanisms of glucose control. Competition remains robust, with established pharmaceutical giants and emerging companies striving for innovation and greater market share. The growing demand for improved diabetes management solutions continues to stimulate research and investment across this dynamic and essential healthcare sector.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 18.02 Billion
Market Size 2030	USD 25.94 Billion
CAGR 2025-2030	6.22%
Fastest Growing Segment	Hospitals
Largest Market	North America

Key Market Drivers

Increasing Global Diabetes Prevalence

The rapidly growing incidence of diabetes globally is a key force driving the Oral Anti-Diabetic Drugs (OAD) market. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20-79 are living with diabetes in 2024, representing 11.1% of the global adult population. This number is expected to rise to 643 million by 2030 and 853 million by 2050. A 2024 Lancet study further highlights that around 828 million adults were affected by diabetes as of 2022. This sharp increase is attributed to lifestyle changes including physical inactivity, poor nutrition, and population aging. These factors significantly elevate the risk of type 2 diabetes, prompting a surge in demand for effective oral therapies. As the diabetic population grows, so does the need for accessible and reliable medications, underscoring the crucial role of oral anti-diabetic drugs in modern disease management.

Key Market Challenges

High Healthcare Costs

One of the major challenges in the Oral Anti-Diabetic Drugs market is the high cost associated with comprehensive diabetes care. This includes not only medications but also glucose monitoring devices, routine consultations, and hospitalization in case of complications. For many patients-especially in low- and middle-income countries-the affordability and accessibility of these treatments remain significant concerns. The price of oral anti-diabetic drugs forms a substantial part of diabetes-related expenditures, and for those lacking adequate insurance or financial support, these expenses can be burdensome. This economic pressure can result in reduced adherence to treatment regimens, ultimately impacting health outcomes and exacerbating disease progression. Managing these cost-related challenges is essential to ensure broader access to effective diabetes therapies.

Key Market Trends

Personalized Medicine Approaches

Personalized medicine is emerging as a transformative trend in the Oral Anti-Diabetic Drugs market. Recognizing that diabetes is a complex and heterogeneous condition, healthcare providers are moving towards customized treatment strategies tailored to each patient's genetic makeup, comorbidities, and personal preferences. Advances in genetic testing and biomarker analysis now allow for more accurate drug selection and dosing, enhancing treatment efficacy while reducing the risk of adverse effects. The shift away from a "one-size-fits-all" model is improving patient outcomes and safety. Personalized therapies are particularly valuable in complex cases where standard treatments may not deliver optimal results, making this trend a key driver of innovation and patient satisfaction in the market.

Key Market Players

KONINKLIJKE PHILIPS N.V.
Sanofi S.A.
Eli Lilly and Company
AstraZeneca
Astellas Pharma Inc.
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck And Co.
Bristol Myers Squibb Company
Novartis AG

Report Scope:

In this report, the Global Oral Anti-Diabetic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Anti-Diabetic Drugs Market, By Drugs:

Biguanides
Alpha-glucosidase inhibitors
Dopamine -D2 Receptor Agonist
Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
Sulfonylureas
Meglitinides

Oral Anti-Diabetic Drugs Market, By End Users:

Hospitals
Homecare
Speciality Centers
Others

Oral Anti-Diabetic Drugs Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Anti-Diabetic Drugs Market.

Available Customizations:

Global Oral Anti-Diabetic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Anti-Diabetic Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides)
- 5.2.2. End Users (Hospitals, Homecare, Speciality Centres, Others)
- 5.2.3. By Company (2024)
- 5.2.4. By Region
5.3. Market Map

6. North America Oral Anti-Diabetic Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drugs
- 6.2.2. By End Users
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Oral Anti-Diabetic Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drugs
    - 6.3.1.2.2. By End Users
- 6.3.2. Mexico Oral Anti-Diabetic Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drugs
    - 6.3.2.2.2. By End Users
- 6.3.3. Canada Oral Anti-Diabetic Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drugs
    - 6.3.3.2.2. By End Users

7. Europe Oral Anti-Diabetic Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drugs
- 7.2.2. By End Users
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Oral Anti-Diabetic Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drugs
    - 7.3.1.2.2. By End Users
- 7.3.2. Germany Oral Anti-Diabetic Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drugs
    - 7.3.2.2.2. By End Users
- 7.3.3. United Kingdom Oral Anti-Diabetic Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drugs
    - 7.3.3.2.2. By End Users
- 7.3.4. Italy Oral Anti-Diabetic Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drugs
    - 7.3.4.2.2. By End Users
- 7.3.5. Spain Oral Anti-Diabetic Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drugs
    - 7.3.5.2.2. By End Users

8. Asia-Pacific Oral Anti-Diabetic Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drugs
- 8.2.2. By End Users
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Oral Anti-Diabetic Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drugs
    - 8.3.1.2.2. By End Users
- 8.3.2. India Oral Anti-Diabetic Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drugs
    - 8.3.2.2.2. By End Users
- 8.3.3. South Korea Oral Anti-Diabetic Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drugs
    - 8.3.3.2.2. By End Users
- 8.3.4. Japan Oral Anti-Diabetic Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drugs
    - 8.3.4.2.2. By End Users
- 8.3.5. Australia Oral Anti-Diabetic Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drugs
    - 8.3.5.2.2. By End Users

9. South America Oral Anti-Diabetic Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drugs
- 9.2.2. By End Users
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Oral Anti-Diabetic Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drugs
    - 9.3.1.2.2. By End Users
- 9.3.2. Argentina Oral Anti-Diabetic Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drugs
    - 9.3.2.2.2. By End Users
- 9.3.3. Colombia Oral Anti-Diabetic Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drugs
    - 9.3.3.2.2. By End Users

10. Middle East and Africa Oral Anti-Diabetic Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drugs
- 10.2.2. By End Users
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Oral Anti-Diabetic Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drugs
    - 10.3.1.2.2. By End Users
- 10.3.2. Saudi Arabia Oral Anti-Diabetic Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drugs
    - 10.3.2.2.2. By End Users
- 10.3.3. UAE Oral Anti-Diabetic Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drugs
    - 10.3.3.2.2. By End Users

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Drugs

15. Competitive Landscape

15.1. KONINKLIJKE PHILIPS N.V.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (In case of listed companies)
- 15.1.5. Recent Developments
- 15.1.6. SWOT Analysis
15.2. Sanofi S.A.
15.3. Eli Lilly and Company
15.4. AstraZeneca
15.5. Astellas Pharma Inc.
15.6. Johnson & Johnson (Janssen Pharmaceuticals)
15.7. Boehringer Ingelheim
15.8. Merck And Co.
15.9. Bristol Myers Squibb Company
15.10. Novartis AG